Key result
Type 2 diabetes is linked to up to ~6-fold higher cardiovascular disease and mortality risk.
Answers are grounded in this paper and cite their sources.
Reviews shared inflammatory pathways linking type 2 diabetes with atherosclerosis, suggesting anti-inflammatory therapies may mitigate excess cardiovascular risk.
Type 2 diabetes carries a 2-6-fold increased risk of cardiovascular disease (CVD) and death. Indeed, the risk of major cardiovascular events in Type 2 diabetic patients without history of coronary heart disease (CHD) is equivalent to that observed in non-diabetic subjects with CHD. However, atherosclerosis may also precede the development of diabetes, suggesting that both disorders share common genetic and environmental antecedent factors ("common soil" hypothesis). One such a possible ancestor is insulin resistance which constitutes both a major feature of Type 2 diabetes and an independent risk factor for CHD. It is well documented that inflammatory processes play an important role in the causation of atherosclerotic CVD. Inflammatory mediators play a paramount role in the initiation, progression, and rupture of atherosclerotic plaques. Thus, markers of inflammation and endothelial dysfunction may provide additional information about a patient's risk of developing CVD and may become new targets for treatment. On the other hand, evidence has emerged suggesting that inflammation is also involved in the development of Type 2 diabetes. Prospective studies have demonstrated that increased levels of pro-inflammatory markers such as CRP or reduced levels of anti-inflammatory markers such as adiponectin predict the development of Type 2 diabetes. Thus, there is accumulating evidence suggesting that inflammation is the bridging link between atherosclerosis and the metabolic syndrome. Interventions by lifestyle modification or agents with anti-inflammatory properties may reduce the risk of both conditions. Drugs exerting anti-inflammatory and vascular effects have future potential to be used within an array of interventions aimed at reducing the enormous cardiovascular burden associated with Type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Dan Ziegler (2005) conducted a review in Type 2 diabetes and atherosclerotic cardiovascular disease. Systemic inflammation was evaluated on Cardiovascular disease and death. Type 2 diabetes carries a 2- to 6-fold increased risk of cardiovascular disease and death, with systemic inflammation serving as a bridging link between atherosclerosis and metabolic syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: